MannKind Corporation
Use of Ultrarapid Acting Insulin

Last updated:

Abstract:

Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.

Status:
Application
Type:

Utility

Filling date:

16 Apr 2019

Issue date:

10 Oct 2019